MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
INBX - Inhibrx Inc
$30.35
-3.71(-10.89%)9:00:00 PM 1/27/2021
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news